Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HY-022619
- Development stage
- Unknown
- Lead developer
- Hefei Medical and Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
HY-022619 is an investigational drug developed by Hefei Medical and Pharmaceutical Co., Ltd. It is currently in Phase 1 clinical trials, where it is being evaluated for safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy adult subjects. The available study compares the effects of a single intravenous injection of HY-022619 with oral ticagrelor, suggesting that the drug may be related to antiplatelet or cardiovascular indications. However, the precise mechanism of action and molecular target have not been disclosed in public sources[1].
- Other names
- HY-022619HY022619HY 022619
Beyond the preview
Go deeper on HY-022619.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HY-022619.